Elekta and Philips Gain MD Anderson Cancer Center as Collaborator in Research Consortium on MRI-Guided Radiation Therapy

Elekta and Philips Gain MD Anderson Cancer Center as Collaborator in Research
                  Consortium on MRI-Guided Radiation Therapy

The University of Texas MD Anderson Cancer Center joins group dedicated to
developing the next-generation innovation for treatment of cancer patients
using radiotherapy

PR Newswire

ATLANTA, Jan. 24, 2013

ATLANTA, Jan. 24, 2013 /PRNewswire/ --Elekta (NSE: EKTAb) and Royal Philips
Electronics (NYSE: PHG, AEX: PHIA) announced today that The University of
Texas MD Anderson Cancer Center (Houston, Texas) has signed an agreement to
join a research group to advance the development of an innovative image-guided
treatment technology for cancer care. The technology merges radiation therapy
and magnetic resonance imaging (MRI) technology in a single system. MD
Anderson is the second member of the research consortium, which will comprise
leading radiation oncology centers and clinicians, and already includes the
University Medical Center Utrecht (the Netherlands).

Uniting state-of-the-art MRI with a cutting edge radiation therapy system –
thus creating an MRI-guided radiation therapy system – will provide physicians
with exceptional images of a patient's soft tissues and tumor during radiation
therapy. This breakthrough innovation also aims to enable clinicians to adapt
treatment delivery in real time for the most precise cancer treatments
possible.

"The special capabilities of the MRI-guided radiation therapy system –
MR-based soft tissue imaging performed simultaneously with treatment delivery
– could revolutionize cancer care," says Jay Hoey, Executive Vice President,
Elekta North America. "Patients are the ultimate winners, because MR imaging
will help put the therapeutic radiation right on target, with the potential to
avoid exposure to normal tissues. My colleagues at Elekta, Philips and
University Medical Center Utrecht are thrilled to welcome MD Anderson to the
research consortium, which will profit immensely from this center's
high-caliber medical, technological and patient care expertise."

"MRI is the gold standard modality for imaging soft tissues, and MR imaging of
the cancer during radiation therapy could provide the health care team the
ability to optimize treatment while reducing toxicity," says Steven J. Frank,
M.D., Associate Professor of Radiation Oncology and Director of Advanced
Technologies at MD Anderson. "Our collaborative research will focus on what
this combination could mean for patients in the future."

"The development of a meaningful, yet complex innovation like the MRI-guided
radiation therapy system can only be done in partnership with leading
healthcare innovators, both from an industrial, as well as a clinical
perspective," says Gene Saragnese, CEO Imaging Systems at Philips Healthcare.
"As a leading innovator in cancer care, the University of Texas MD Anderson
Cancer Center will bring their unique expertise to help realize the promise of
more targeted cancer treatments and transform the way healthcare is delivered
today."

Prior to the establishment of the research consortium, Elekta, Philips and the
University Medical Center Utrecht have built and tested a prototype system
that integrates a linear accelerator and a 1.5 Tesla MRI system. The success
of these efforts has enabled the project to move to the next phase of
development and testing by the select group of consortium partners.

Radiation therapy and medical imaging already play an essential role in
treatment planning, delivery and after care, and are proven, cost-effective
and safe methods for the treatment of individuals with cancer. Radiotherapy is
a critical modality for cancer treatment, either as a frontline treatment or
used with other modalities, such as chemotherapy. The procedure involves
identifying cancerous tissue and irradiating it with high-energy radiation
beams in a way that maximizes sparing of healthy tissues near the tumor. 

The integrated MRI-guided radiation therapy system is in development and not
available for sale.

For further information, please contact:

Michelle Joiner, Director, Global Public Relations and Brand Management,
Elekta
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

Steve Klink, Philips Corporate Communications
Tel: +31 20 5977415, email: steve.klink@philips.com

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow
enhancing software systems across the spectrum of cancer care. Stretching the
boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare
providers and patients, Elekta aims to improve, prolong and even save patient
lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,400 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.

About Royal Philips Electronics

Royal Philips Electronics (NYSE: PHG, AEX: PHI) is a diversified health and
well-being company, focused on improving people's lives through meaningful
innovation in the areas of Healthcare, Consumer Lifestyle and Lighting.
Headquartered in the Netherlands, Philips posted 2011 sales of EUR 22.6
billion and employs approximately 122,000 employees with sales and services in
more than 100 countries. The company is a leader in cardiac care, acute care
and home healthcare, energy efficient lighting solutions and new lighting
applications, as well as male shaving and grooming, home and portable
entertainment and oral healthcare. News from Philips is located at
www.philips.com/newscenter.

SOURCE Elekta

Website: http://www.elekta.com